FAS and cancer: Individuals who carried both FAS-1377(GG+GA)/FASL-844(TT+TC) genotypes had a decreased cancer risk compared to those who carried both FAS-1377 AA/FASL-844 CC genotypes (OR = 0.47, 95% CI = 0.25-0.90, Pheterogeneity = 0.000, P = 0.023) (Table 2, Figure 5).